Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 7, 2013, Pages 839-847

  Lagging, Martin ^a   Rembeck, Karolina ^a   Rauning Buhl, Mads ^b   Christensen, Peer ^c   Dalgard, Olav ^d   Färkkilä, Martti ^e   Hellstrand, Kristoffer ^a   Langeland, Nina ^f   Lindh, Magnus ^a   Westin, Johan ^a   Norkrans, Gunnar ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF BERGEN   (Norway)

Author keywords

CXCL10; Genotype 2; genotype 3; HCV; IL28B; Hepatitis C Virus; Interferon; IP 10; Relapse; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENOTYPE; GROUPS BY AGE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETREATMENT; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84880472787     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.793389     Document Type: Article

References (33)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65
2. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
3. Alsio A, Rembeck K, Askarieh G, Christensen PB, Farkkila M, Langeland N, et al. Impact of obesity on the bioavailability of peginterferon-alpha2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS One 2012;7:e37521
4. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837-45
5. Berg C, Goncales FL Jr, Bernstein DE, Sette H Jr, Rasenack J, Diago M, et al. Re-treatment of chronic hepatitis C patients after relapse: Efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat 2006;13:435-40
6. Floreani A, Cazzagon N, Furlan P, Baldovin T, Egoue J, Antoniazzi S, et al. Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment. Eur J Gastroenterol Hepatol 2011;23:711-15
7. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and retreatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009;49:358-63
8. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618- 28; e2
9. Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, et al. Once daily Psi-7977 plus Rbv: Pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV Gt2 or Gt3. Hepatology 2011;54:377A-A.
10. Lindh M, Lagging M, Farkkila M, Langeland N, Morch K, Nilsson S, et al. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011;203:1748-52
11. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9
12. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37: 837-42
13. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518- 26
14. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005;40:867-72
15. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, Westin J, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011;6:e17232
16. Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006;44:1617-25
17. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, et al. Interferon (IFN)-gamma-inducible protein- 10: Association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006;194:895-903
18. Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, Neumann AU, et al. Systemic and intrahepatic interferongamma- inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010;51: 1523-30
19. Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, et al. IL28B alleles associated with poor HCV clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012;55:384-94
20. Rembeck K, Alsio A, Christensen PB, Farkkila M, Langeland N, Buhl MR, et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS ONE 2012;7:e29370
21. Rembeck K, Westin J, Lindh M, Hellstrand K, Norkrans G, Lagging M. Association between IL28B-related genetic variants and liver histopathology differs between HCV genotypes. Hepatology 2012;56:394
22. Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011;55:980-8
23. Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, et al. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1 J Viral Hepat 2011;18:e325-31
24. Lindh M, Lagging M, Farkkila M, Langeland N, Morch K, Nilsson S, et al. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011;203:1748-52
25. Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjoro K, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011;53:746-54
26. Lagging M, Alsio A, Langeland N, Pedersen C, Farkkila M, Buhl MR, et al. Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. Hepatology 2011;53: 1067-8
27. Lagging M, Alsio S, Hellstrand K, Norkrans G. Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infectioñ J Hepatol 2011;54:835-6
28. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology 2008;48:695
29. Christensen PB, Krarup HB, Laursen AL, Madsen PH, Pedersen C, Schlichting P, et al. Negative HCVRNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C. Scand J Gastroenterol 2012;47:1115-19
30. Poordad F, Chee GM. Interferon free hepatitis C treatment regimens: The beginning of another era. Curr Gastroenterol Rep 2012;14:74-7
31. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009;49:1460-8
32. Tanwar S, Trembling PM, Dusheiko GM. TMC435 for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2012;1:1193-209
33. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012;56:1247-53